Paba

Quick links to important sections

Paba

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Paba

Understanding PABA

Para-aminobenzoic acid, commonly known as PABA, is a naturally occurring compound. It is often identified as a member of the vitamin B complex family, though it is not technically a vitamin itself but rather a component of folic acid (vitamin B9). It can be found in various foods, including grains, eggs, milk, and organ meats.

Biological Role

In the body, PABA is involved in several biological pathways. It is synthesized by bacteria in the gut and serves as an essential precursor for the production of folate by these microorganisms. While humans do not synthesize folate from PABA in the same way bacteria do, the compound has been studied for its presence in the skin and its interaction with biological processes involving connective tissues and pigmentation.

Historical Context and Applications

Historically, PABA gained recognition for its ability to absorb ultraviolet (UV) light. This characteristic led to its widespread use in early topical formulations designed for sun protection. Beyond topical applications, PABA has been utilized in oral forms for specific conditions involving the skin and connective tissues.

Research has explored its potential effects on:

  • Skin Pigmentation: Investigating its role in addressing areas of skin that have lost natural color.
  • Connective Tissue Disorders: Evaluating how the compound might influence the hardening or fibrous growth of tissues.

Physical Characteristics

In its pure form, PABA typically appears as a white to off-white crystalline powder. It is slightly soluble in water and highly soluble in organic solvents such as alcohol. In consumer products, it is often formulated into tablets, capsules, or topical creams, depending on the intended use.

Regulatory References

  1. MedlinePlus: Combination Drug Information
  2. NIH: PABA Uses
  3. Phenobarbital - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Paba?

Possible Side Effects and Safety Information

The officially documented adverse effects for Paba, a combination product containing Belladonna alkaloids and Phenobarbital, are classified primarily by the physiological system they affect, according to regulatory labeling. Due to the historical nature of this fixed-dose combination, specific frequency categories like 'common' or 'rare' are typically not explicitly assigned in the official prescribing information.

Adverse reactions most frequently noted relate to the anticholinergic and sedative properties of the components:

  • Nervous System Disorders: Drowsiness, sedation, headache, dizziness, and confusion.
  • Gastrointestinal Disorders: Dry mouth, constipation, nausea, and vomiting.
  • Eye and Cardiac Disorders: Blurred vision, sensitivity to light (photophobia), tachycardia (increased heart rate), and palpitations.
  • Urinary and Skin Disorders: Urinary hesitancy or retention, and decreased sweating.

Serious adverse reactions are documented, including blood dyscrasias (such as agranulocytosis) and severe allergic skin reactions. A notable risk, especially in pediatric patients and older adults, is paradoxical excitation, where the medicine causes restlessness, agitation, or confusion instead of sedation.

Safety Considerations and Restrictions

Safety notes specify that effects like drowsiness may be more pronounced during the initial phase of treatment or following a dosage increase. The regulatory label includes mandatory restrictions (contraindications) and advises against the use of Paba in individuals with specific pre-existing conditions, including narrow-angle glaucoma, obstructive uropathy (e.g., bladder neck obstruction), obstructive gastrointestinal diseases, myasthenia gravis, and severe ulcerative colitis. Older adults may exhibit greater sensitivity to the sedative and anticholinergic effects, which is a required consideration in the regulatory documents.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Paba (para-aminobenzoic acid), especially after a large, single exposure, is considered potentially harmful. Immediate medical attention is required if ingestion is suspected or if you experience any concerning symptoms.

Overdose Symptoms

Symptoms reported in regulatory and clinical documents following high-level exposure (e.g., doses of 10,000 mg/day or more) may affect multiple systems, including:

  • Hematological: Methemoglobinemia (a condition where the blood's ability to carry oxygen is reduced, causing blue or slate-gray discoloration of the skin and mucous membranes, known as cyanosis).
  • Gastrointestinal: Nausea and vomiting.
  • Systemic/Metabolic: Acidosis and fever.
  • Dermatological: Pruritus (itching) and rash.
  • Neurological: Severe methemoglobinemia can lead to weakness, dizziness, lightheadedness, severe headache, confusion, and depressed mental status, including stupor or convulsions.

Emergency Actions

Seek urgent medical help immediately by contacting emergency services or a poison control center if a large amount of Paba is swallowed. In a healthcare setting, treatment for a known overdose may involve supportive measures for symptoms like low blood pressure and addressing methemoglobinemia, typically through oxygen delivery and administration of an antidote such as methylene blue for significant methemoglobin levels.

Therapeutic Uses of Paba

What Paba Treats: Main Uses and Benefits

Targeting Painful Spasms and Complex GI Distress

The Paba combination product is used in situations involving certain distressing symptoms related to gastrointestinal discomfort. It may be part of supportive therapy for conditions such as Irritable Bowel Syndrome (IBS) and Spastic Colon. It is commonly used to help with the symptomatic relief of painful abdominal cramping and spasms associated with functional bowel disorders.

It is relevant for easing symptoms that are exacerbated by both excess stomach acidity and accompanying nervous tension. This support contributes to improved day-to-day comfort during periods of heightened symptoms. The medication is applied in clinical settings that involve acute or unstable symptom patterns and helps address symptom clusters that may become intense or disruptive.


Quick Fact

Quick Fact: Support for Recurrent Episodic Symptoms

This medication is applied in scenarios where additional management of discomfort is required, providing supportive relief that helps ease the overall symptom burden during difficult episodes of heightened gut sensitivity.

Regulatory References

  1. DailyMed, National Institutes of Health (NIH) Labeling

Eligibility and Restrictions for Use

The eligibility for using the prescription combination product Paba (containing Belladonna alkaloids and Phenobarbital, among other ingredients) is strictly determined by official regulatory contraindications and population-specific restrictions.

Contraindicated Populations (Must Not Use)

Use is contraindicated in patients with specific severe conditions, primarily due to the anticholinergic and sedative components. These include:

  • Glaucoma
  • Obstructive Uropathy or Obstructive GI Tract Disease
  • Acute Intermittent Porphyria or Severe Ulcerative Colitis
  • A history of drug dependence or known hypersensitivity to any ingredient.

Age- and Condition-Based Restrictions

Population Group Regulatory Status
Hepatic or Renal Dysfunction Caution required; initial doses may need to be small.
Older Adults (Geriatric) Caution required due to heightened sensitivity, risking agitation or drowsiness.
Children and Infants Caution required; severe side effects are more likely to occur.
Pregnancy (Category C) Use only if clearly needed; caution must be exercised in nursing mothers.

Caution is also explicitly required for patients with certain cardiovascular conditions (e.g., cardiac arrhythmias, hypertension) and those with an ileostomy or colostomy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This fixed-dose combination product’s interaction profile is based on the actions of its components: Phenobarbital, Belladonna alkaloids, and Aluminum Hydroxide.

Documented Interaction Patterns

The Phenobarbital component is a potent enzyme inducer of CYP2C9, CYP2C19, and CYP3A4, which results in a pharmacokinetic interaction where co-administered drugs are metabolized faster. This effect officially leads to a reduced systemic exposure and decreased efficacy of medicines such as Warfarin and hormonal oral contraceptives, as documented in regulatory labeling.

Pharmacodynamic interactions primarily involve additive effects. Co-administration with alcohol and other strong CNS depressants (like Sodium Oxybate or certain narcotics) is formally contraindicated due to the risk of potentiating central nervous system depression. Additionally, combining Paba with other anticholinergic agents (e.g., Tricyclic Antidepressants) can officially enhance peripheral anticholinergic effects.

Administration Constraints

The Aluminum Hydroxide component can bind to certain oral agents, including Tetracyclines, Iron Salts, and Thyroxine, thereby reducing their systemic absorption. Regulatory guidelines mandate the separation of administration timing by several hours for these specific medications to avoid this non-systemic binding interaction.

Population-Specific Notes

Official labeling states that interaction severity, particularly related to Phenobarbital, is heightened in patients with hepatic or renal impairment due to the potential for reduced clearance and drug accumulation.

Mechanism of Action

Para-aminobenzoic acid (PABA) is an organic compound that engages two primary, distinct physiological mechanisms: metabolic competition within prokaryotes and physical-chemical light absorption.

Enzyme-Mediated Folate Precursor Activity

PABA serves as a substrate in the bacterial synthesis of folate (vitamin B9). Specifically, it is utilized by the enzyme dihydropteroate synthase, which catalyzes an early molecular step in the folate cascade within bacterial cells. The structural similarity of PABA to specific agents (such as sulfonamides) facilitates competitive inhibition of dihydropteroate synthase, thereby modulating the subsequent folate biosynthetic cascade.

Absorption of Ultraviolet Radiation

PABA modulates the physiological response to external stimuli, specifically within the integumentary system. It acts as an exogenous chromophore by directly absorbing ultraviolet B (UVB) light (wavelengths in the 290–320 nm range). This physical-chemical process influences the ratio of absorbed to transmitted UVB energy, thereby modulating the initiation of cellular stress responses and influencing subsequent molecular events such as photoproduct formation and downstream signaling cascades.

Dosage and Administration Information

The combination product Paba (Belladonna Alkaloids with Phenobarbital) is strictly an oral medication administered in several forms, including immediate-release (IR) tablets or elixir, and extended-release (ER) tablets. Standard usage patterns emphasize that the dosage must be individualized to the patient's specific needs.


Field Content
Route of administration Oral administration is the exclusive approved route.
Dosing schedule Immediate-Release: One to two tablets or 5 to 10 mL of elixir per dose. Extended-Release: One tablet per dose.
Frequency and Timing IR forms are administered three or four times daily, typically 30 minutes before meals and at bedtime. Extended-release tablets are administered every 8 to 12 hours.
Preparation / Handling The liquid elixir form requires measurement using a calibrated device. Extended-release tablets must be swallowed whole and must not be crushed, cut, or chewed.
Age-group rules Older Adults: A smaller initial dose and cautious adjustment may be necessary. Pediatrics: The elixir form has specific weight-based dosing for children; ER tablets are generally not recommended.
Use-context constraints Dosage must be adjusted to the individual patient's needs to achieve symptomatic control.

This standardized administration protocol defines the precise conditions and schedule under which the medication is taken. The structure mandates the exclusive oral route and a defined, divided-daily dosing schedule that depends on the formulation used. This protocol is further defined by strict instructions for physical handling of the extended-release formulation and the requirement for dose flexibility across different patient populations.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Paba

This overview summarizes the official and peer-reviewed research available for the Paba combination product, focusing on the types of studies conducted and the patterns observed, without providing individual medical advice or clinical recommendations.


Evidence for Symptomatic Relief in Irritable Bowel Syndrome (IBS) and Spastic Colon

Paba was studied for conditions characterized by fluctuating or episodic manifestations of physical discomfort, such as Irritable Bowel Syndrome (IBS) and Spastic Colon. The research supporting this use primarily consists of older clinical trials and regulatory assessments, and the Belladonna alkaloids component was evaluated in studies exploring outcomes related to spasms.

These studies explored how symptoms change over time and focused on outcomes related to painful abdominal cramping and spasms. Researchers used patient-reported outcomes describing perceived discomfort to monitor how symptoms evolved in the observed populations during the study period. Findings describe patterns observed in these studies that involved changes in the frequency of painful episodes.


Evidence for Management of Multi-faceted Gastrointestinal Discomfort

The Paba combination was evaluated in research exploring temporary physiological imbalance, specifically in conditions characterized by outcomes linked to irritative states. Research has explored the contributions of the individual components, such as Aluminum Hydroxide, with studies monitoring patient-reported outcomes describing perceived discomfort related to acid, and Phenobarbital, evaluated in research exploring nervous tension.

Studies monitored outcomes linked to inflammatory or irritative states, focusing on how symptoms evolved in the observed populations in acute settings. Data show patterns related to short-term symptom easing, often measured over very defined time intervals following an acute dose. This evidence contributes to understanding symptom patterns, particularly for episodes where symptoms are heightened or disruptive.


Key Uncertainties and Research Gaps

For this fixed-dose combination, the evidence base has several acknowledged limitations, and certainty remains low in certain areas. Sample sizes were modest in many of the older trials, and evidence quality varies across studies. Specifically, there is a lack of recent, high-quality, placebo-controlled RCTs that use current, standardized outcome measures for functional limitations. Long-term effects are not fully established, and comparative evidence is lacking, limiting the ability to draw firm, consistent conclusions.

Key Studies & References

  1. DailyMed: Belladonna Alkaloids and Phenobarbital (Official Drug Labeling)
  2. NIH Bookshelf: P-Aminobenzoic Acid (PABA) Uses and Classification
  3. MedlinePlus: Combination Drug Information Overview

Frequently Asked Questions (FAQ)

Common questions about Paba (FAQ)

Q: What are the main benefits of PABA according to people who use it?

A: Official health sources indicate that PABA (Para-aminobenzoic acid) has been approved by the FDA for use as a sunscreen to filter UV light. The substance is also used and studied for a specific condition that causes penile curvature (Peyronie disease). Evidence for many other proposed uses, such as hardening of the skin (scleroderma), is considered limited.


Q: Does PABA help with skin conditions like vitiligo?

A: PABA has historically been studied and proposed for use in treating conditions like vitiligo, which causes patches of skin to lose their color. However, regulatory and government-backed sources state that there is currently insufficient reliable evidence to strongly support PABA for this use.


Q: What are the most commonly reported side effects of PABA?

A: When PABA is taken by mouth, common side effects noted in official documentation include gastrointestinal issues such as nausea, vomiting, and upset stomach, as well as loss of appetite (anorexia) and skin rash.


Q: Is it normal to feel slightly nauseous after taking PABA?

A: Nausea is specifically listed in official product information as one of the possible side effects associated with taking PABA by mouth. Experiencing an upset stomach or nausea is a recognized adverse effect.


Q: Are there any known serious side effects from PABA supplementation?

A: According to official documentation, PABA taken by mouth in very high daily amounts is considered potentially unsafe. This high level of use has been associated with reports of serious effects on the liver and kidneys.


Q: Does PABA interact with blood thinners or aspirin?

A: Official interaction information states that PABA might have a tendency to slow blood clotting, especially when administered intravenously. If PABA is used alongside medications that also slow clotting (such as certain blood thinners and aspirin), this combination may increase the risk of bleeding or bruising.


Q: Does PABA interact with antibiotics?

A: Yes, PABA is known to interact with certain medications. Official documentation states that PABA can potentially decrease the effectiveness of a class of antibiotics known as sulfonamides (or sulfa antibiotics).


Q: Who should generally avoid taking PABA supplements?

A: PABA is considered potentially unsafe when taken by mouth in high doses, and caution is needed for certain groups. Those with pre-existing kidney disease or individuals with bleeding disorders should exercise caution, as PABA could potentially worsen their conditions or increase the risk of bleeding.


Q: Is PABA safe for teenagers to take?

A: Official sources indicate that PABA is generally considered possibly safe for children when taken by mouth in appropriate amounts. However, there are no specific regulatory guidelines detailing the safety profile or suitable doses for teenagers.


Q: What is the research evidence supporting PABA's use for skin health?

A: PABA is FDA-approved for use as a sunscreen because its chemical structure allows it to effectively filter UVB radiation and protect the skin from sunburn. Evidence for its use in treating other specific skin diseases is mixed, and support for those purposes is limited.


Q: What is the difference between PABA and folic acid?

A: PABA is a nonessential nutrient, meaning the body does not strictly require an external source. Chemically, PABA is actually a component of the folic acid molecule (Vitamin B9); for this reason, it was historically given the name 'vitamin Bx,' though it is not classified as a true B vitamin today.


Q: Is PABA considered safe for long-term use?

A: Very high daily amounts are clearly associated with serious risks to the liver. Furthermore, the FDA previously proposed that PABA is not GRASE (Generally Recognized as Safe and Effective) for use as a sunscreen due to concerns about high systemic absorption and safety risks.


Q: What is the typical experience of people taking PABA for connective tissue issues?

A: PABA is studied and used for treating Peyronie disease, a type of connective tissue disorder. Studies suggest that PABA is possibly effective and tends to improve symptoms of the disease, though it may not reduce existing plaque formation.


Q: How does PABA work inside the body at a basic level?

A: PABA is a chemical substrate, which means it serves as a foundation for other processes. Specifically, it plays a role in the bacterial synthesis of folate (Vitamin B9). It also functions as a chromophore (light absorber) when applied topically to the skin to filter UV light.


Q: Is PABA naturally found in any foods?

A: Yes, PABA naturally occurs in several different food sources. Common foods that contain PABA include grains, eggs, milk, and meat.


Q: Is it true that PABA can sometimes cause liver issues?

A: Yes, PABA is considered possibly unsafe in very high daily amounts. Official reports have specifically associated this level of usage with instances of liver toxicity or injury, which typically resolve once the product is stopped.


Q: What are the common signs of taking too much PABA?

A: Taking excessive doses of PABA (specifically very high daily amounts) is associated with serious risks. These risks include the potential for developing liver and kidney problems.


Q: How is PABA related to the formation of red blood cells?

A: PABA is a component of the folic acid molecule (Vitamin B9). Folic acid is an essential nutrient required by the body for several processes, including the proper formation and maturation of red blood cells.


Q: Can pregnant women safely use topical PABA products?

A: Official health sources indicate that PABA is likely safe for use when applied topically (to the skin) during pregnancy or while breastfeeding. However, there is not enough reliable information available to confirm if taking PABA by mouth is safe for these populations.


Q: Why is PABA sometimes combined with other B vitamins?

A: PABA is often included in B-complex supplements because it is a direct structural part of the folic acid (B9) molecule. Due to this structural link, PABA was historically classified alongside the B vitamins and sometimes referred to as 'vitamin Bx.'


Q: What is the absorption rate of PABA when taken as a supplement?

A: Studies on the pharmacokinetics (how the body handles the substance) of PABA have shown that it is generally well-absorbed when taken as an oral supplement. Research indicates that almost all of the administered dose (around 93% to 99%) can be recovered in the urine within 24 hours.


Q: Does PABA have any known effect on energy levels?

A: Some studies suggest that PABA may have the potential to interfere with the activity of the thyroid gland. Because the thyroid helps regulate metabolism and influences symptoms like fatigue, this could theoretically have an impact on a person's energy levels.


Q: Are there different forms of PABA that are better absorbed?

A: Clinical studies comparing different forms of PABA—such as tablets, capsules containing the potassium salt, and PABA naturally found in food—found that all had a similarly high absorption rate. Most of the administered PABA was efficiently absorbed and recovered from the body.


Q: Can PABA supplements cause skin rashes or itching?

A: Yes, regulatory documentation lists rash as a potential side effect of PABA supplementation. Furthermore, PABA has long been associated with a potential risk of allergic reactions and irritation when applied to the skin.


Q: What are people's experiences with PABA for conditions like Peyronie's disease?

A: PABA is a treatment studied and used for Peyronie disease, a condition affecting the penis. Official research indicates that it is considered possibly effective and is used to improve the symptoms associated with the disease.


Q: Is PABA naturally produced by the body?

A: The human body does not have the enzymes necessary to produce PABA itself. However, the bacteria that naturally live in the human gut (the microbiome) are capable of producing PABA.


Q: What is the historical use of PABA in medicine?

A: Historically, PABA was widely used and highly valued as a chemical UVB filter in sunscreens for its effectiveness. It eventually fell out of favor in many formulations primarily due to issues it caused, such as skin sensitization and staining of clothing.


Q: Is there a maximum recommended daily intake for PABA?

A: While specific recommended daily intakes may vary, official safety warnings emphasize that taking PABA at very high daily amounts is considered possibly unsafe. These high levels are linked to severe adverse effects, including damage to the liver and kidneys.


Q: What is the difference between oral PABA and topical PABA cream?

A: There is a difference in the safety profile based on the route of administration. Topical PABA (used in sunscreens) is considered likely safe. However, oral PABA is only considered possibly safe in appropriate doses and carries a greater risk of serious side effects, such as liver damage, when taken in high amounts.

How should Paba be stored and disposed of?

Storage and Disposal Conditions

The storage of the Paba combination product (Aluminum Hydroxide, Belladonna alkaloids, Phenobarbital, Procaine) must comply with requirements documented in official drug labeling to maintain stability and ensure safety.

Storage Requirements

The medicine must be stored at controlled room temperature, typically 20 °C to 25 °C (68 °F to 77 °F). It is essential to protect the product from moisture and excessive heat and to keep it in a tightly closed container.

Child Safety

Official labeling mandates that the medication be stored out of the reach of children due to the potential toxicity of its components, particularly Phenobarbital and Belladonna alkaloids.

Disposal Instructions

Unused or expired product should not be flushed down the toilet or poured into a drain. The preferred method for disposal is using a medicine take-back program. If a program is unavailable, the product must be rendered unappealing by mixing it with a substance like dirt or coffee grounds, sealing it in a plastic bag, and then discarding it with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Paba found in:

A-Z Index: